CVS Health withholds coverage for new HIV prevention drug

CVS Health, one of the nation’s largest pharmacy benefit manager companies that play a lead role in deciding which drugs are covered by health insurance plans, has initially decided not to approve coverage for the new HIV prevention drug Yeztugo

Developed and manufactured by the pharmaceutical company Gilead Sciences, Yeztugo was approved for use in June of this year by the U.S. Food and Drug Administration as an HIV prevention or PrEP medication that needs to be taken just twice a year by injection.

HIV prevention advocates hailed the new drug as a major breakthrough in the years long effort to curtail and end the HIV/AIDS epidemic by enabling far more people at risk for HIV infection to adhere to a prevention drug regimen that needed to be taken once every six months rather than daily